Last10K.com

21St Century Oncology Holdings, Inc. (RTSX) SEC Filing 10-Q Quarterly report for the period ending Tuesday, June 30, 2015

21St Century Oncology Holdings, Inc.

CIK: 1503518 Ticker: RTSX

Exhibit 99.1

 

 

21ST CENTURY ONCOLOGY HOLDINGS, INC.

 

21st Century Oncology Contact:

Investor Contact:

Richard Lewis

The Ruth Group

SVP, CFO for U.S. Operations

Nick Laudico

239-931-7281

646-536-7030

richard.lewis@21co.com

nlaudico@theruthgroup.com

 

 

 

Brandon Vazquez

 

646-536-7032

 

bvazquez@theruthgroup.com

 

21ST CENTURY ONCOLOGY HOLDINGS INC. REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS

 

Second Quarter 2015 Highlights:

 

·                  Total pro forma revenues of $285.2 million, a 7.3% year-over-year increase

·                  Pro Forma Adjusted EBITDA of $51.1 million, a 13.0% year-over-year increase

·                  6th consecutive quarter of Pro Forma Adjusted EBITDA margin expansion — 17.9% of total pro forma revenues

·                  International revenues up 27.9% year-over-year

·                  Completed $1.1 billion debt refinancing that extended debt maturities and provided additional liquidity

 

Recent Developments:

 

·                  Completed the acquisition of remaining 35% interest in South Florida Radiation Oncology (“SFRO”), proceeding with integration

·                  Expanded into Colombia through a controlling investment interest in an existing Medellin-based hospital center

 

FORT MYERS, FL, August 11, 2015 — 21

st Century Oncology Holdings, Inc. (“21C” or the “Company”), the leading global, physician-led provider of integrated cancer care services (“ICC”), announced today its financial results for the second quarter ended June 30, 2015.

 

Dr. Daniel Dosoretz, Founder, President and Chief Executive Officer, commented, “We  achieved our revenue and EBITDA targets for the quarter and the first six months of 2015 through same store growth, contributions from acquisitions, strong results from our international operations, and executing on our savings and synergy programs. This marks our sixth consecutive quarter of Pro Forma Adjusted EBITDA (adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation and other non-cash and pro forma items) margin expansion, the result of leveraging existing overhead over a larger revenue base. We remain on track to achieve our full year 2015 Pro Forma Adjusted EBITDA guidance of between $182 million and $190 million. 21C’s management team remains focused on further expense

 


The following information was filed by 21St Century Oncology Holdings, Inc. (RTSX) on Tuesday, August 11, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate 21St Century Oncology Holdings, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by 21St Century Oncology Holdings, Inc..

Continue

Assess how 21St Century Oncology Holdings, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

21St Century Oncology Holdings, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Cash Flows (parenthetical)
Condensed Consolidated Statements Of Operations And Comprehensive Loss
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Acquisitions And Other Arrangements
Acquisitions And Other Arrangements (narrative) (details)
Acquisitions And Other Arrangements (schedule Of Estimated Future Amortization Expense) (details)
Acquisitions And Other Arrangements (schedule Of Preliminary Intangible Assets Included In Net Identifiable Assets) (details)
Acquisitions And Other Arrangements (schedule Of The Allocation Of The Purchase Price) (details)
Acquisitions And Other Arrangements (schedule Of Unaudited Pro Forma Financial Information) (details)
Acquisitions And Other Arrangements (summary Of Allocation Of The Aggregate Purchase Price, Including Assumed Liabilities) (details)
Acquisitions And Other Arrangements (tables)
Basis Of Presentation
Basis Of Presentation (details)
Basis Of Presentation (policy)
Commitments And Contingencies
Commitments And Contingencies (details)
Comprehensive Loss
Comprehensive Loss (narrative) (details)
Comprehensive Loss (schedule Of Components Of Accumulated Other Comprehensive Loss) (details)
Comprehensive Loss (tables)
Derivative Agreements
Derivative Agreements (narrative) (details)
Fair Value Of Financial Instruments
Fair Value Of Financial Instruments (narrative) (details)
Fair Value Of Financial Instruments (schedule Of Changes In Level 3 Liabilities) (details)
Fair Value Of Financial Instruments (schedule Of Fair Value Debt Instruments Based On Level 2) (details)
Fair Value Of Financial Instruments (schedule Of Items Measured At Fair Value On Recurring Basis) (details)
Fair Value Of Financial Instruments (tables)
Goodwill
Goodwill (narrative) (details)
Goodwill (schedule Of Changes In The Carrying Amount Of Goodwill) (details)
Goodwill (schedule Of Impairment Loss) (details)
Goodwill (tables)
Income Taxes
Income Taxes (details)
Leverage And Liquidity
Leverage And Liquidity (details)
Long-term Debt
Long-term Debt (narrative) (details)
Long-term Debt (schedule Of Company's Long-term Debt) (details)
Long-term Debt (schedule Of Financial Covenants Compliance Under The Revolving Credit Facility) (details)
Long-term Debt (tables)
Organization
Organization (details)
Reconciliation Of Total Equity
Reconciliation Of Total Equity (details)
Reconciliation Of Total Equity (tables)
Redeemable Preferred Stock
Redeemable Preferred Stock (narrative) (details)
Redeemable Preferred Stock (schedule Of Changes To Series A Preferred Stock) (details)
Redeemable Preferred Stock (tables)
Segment And Geographic Information
Segment And Geographic Information (narrative) (details)
Segment And Geographic Information (schedule Of Financial Information By Geographic Segment) (details)
Segment And Geographic Information (schedule Of Reconciliation Of The Company's Reportable Segment Profit And Loss) (details)
Segment And Geographic Information (tables)
Stock-based Compensation
Stock-based Compensation (narrative) (details)
Stock-based Compensation (summary Of Units Activity Under The Plan) (details)
Stock-based Compensation (tables)
Supplemental Consolidating Financial Information
Supplemental Consolidating Financial Information (narrative) (details)
Supplemental Consolidating Financial Information (schedule Of Condensed Consolidating Balance Sheet) (details)
Supplemental Consolidating Financial Information (schedule Of Condensed Consolidating Statement Of Cash Flows) (details)
Supplemental Consolidating Financial Information (schedule Of Condensed Consolidating Statements Of Operations And Comprehensive Income (loss)) (details)
Supplemental Consolidating Financial Information (tables)

Material Contracts, Statements, Certifications & more

21St Century Oncology Holdings, Inc. provided additional information to their SEC Filing as exhibits

Ticker: RTSX
CIK: 1503518
Form Type: 10-Q Quarterly Report
Accession Number: 0001104659-15-060073
Submitted to the SEC: Fri Aug 14 2015 4:29:47 PM EST
Accepted by the SEC: Fri Aug 14 2015
Period: Tuesday, June 30, 2015
Industry: Offices And Clinics Of Doctors Of Medicine

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/rtsx/0001104659-15-060073.htm